Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Cash from Financing Activities (2021 - 2025)

Kezar Life Sciences' Cash from Financing Activities history spans 5 years, with the latest figure at -$1.3 million for Q3 2025.

  • For Q3 2025, Cash from Financing Activities changed N/A year-over-year to -$1.3 million; the TTM value through Sep 2025 reached -$3.8 million, down 3431.3%, while the annual FY2024 figure was $103000.0, 83.86% down from the prior year.
  • Cash from Financing Activities for Q3 2025 was -$1.3 million at Kezar Life Sciences, down from -$1.3 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $99.4 million in Q4 2021 and bottomed at -$1.3 million in Q3 2025.
  • The 5-year median for Cash from Financing Activities is $185000.0 (2022), against an average of $14.0 million.
  • The largest annual shift saw Cash from Financing Activities skyrocketed 27673.76% in 2022 before it plummeted 2366.07% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $99.4 million in 2021, then crashed by 99.49% to $506000.0 in 2022, then plummeted by 88.34% to $59000.0 in 2023, then fell by 20.34% to $47000.0 in 2024, then plummeted by 2876.6% to -$1.3 million in 2025.
  • Per Business Quant, the three most recent readings for KZR's Cash from Financing Activities are -$1.3 million (Q3 2025), -$1.3 million (Q2 2025), and -$1.3 million (Q1 2025).